EMEA-000734-PIP01-09
Key facts
| Active substance |
[(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl) propoxy] biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hydrate (TAK-875)
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/243/2010
|
| PIP number |
EMEA-000734-PIP01-09
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Takeda Global Research and Development Centre (Europe) Ltd.
paediatrics@tgrd.com
Phone: +44 2031168237 Fax: +44 2031168250 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|